Navigation Links
Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting

Data on six products from Pharmion's pipeline provide support for epigenetic and combination therapies, including promising Phase III data on use of Thalidomide to treat multiple myeloma

BOULDER, Colo., May 31, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from 18 abstracts of studies investigating the company's marketed and pipeline products will be presented or published at the American Society of Clinical Oncology's (ASCO) 43rd Annual Meeting in Chicago (June 1-5, 2007). These abstracts include summaries of data from studies of each of the six key products in the company's commercial and development portfolio, for multiple indications, including Myelodysplastic Syndromes (MDS), multiple myeloma, Hodgkin's lymphoma, small cell lung cancer and advanced hormone-refractory prostate cancer.

"ASCO 2007 provides further evidence of Pharmion's progress," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "Data from six of our products will be presented or published, including Phase III data for Satraplatin and Thalidomide, encouraging Phase II data for Amrubicin, Vidaza and MGCD0103, and human bioavailability data for oral azacitidine. These data demonstrate the strength of the Pharmion business model; we are focused solely on oncology, we have multiple compounds demonstrating clinical benefit, and we have a U.S. and international infrastructure to support those products. Pharmion is well-positioned to take full advantage of the strong portfolio of products in our pipeline."

"The data at ASCO affirm Pharmion's leadership in developing epigenetic therapies as a promising approach to treating cancer," said Andrew R. Allen, Pharmion's chief medical officer. "MGCD0103, our class-selective HDAC inhibitor, is showing meaningful activity as monotherapy in advanced Hodgkin's lymphoma. Furthermore, as we begin to understand the way in which multiple epigen
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Orthopedic Soft Tissue Repair ... About Orthopedic Soft Tissue ... of cells that connect, support, or surround bones. ... such as tendons, ligaments, cartilage, fascia, and other ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
(Date:8/27/2014)... Mass. , Aug. 27, 2014 Decision ... that characterized the Memphis health ... way to clinical integration, with rivals Methodist Le Bonheur ... respective physician groups to coordinate patient care. In addition, ... which has the most health plan enrollment in the ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 2011 Centre Partners Management LLC ("Centre Partners"), a leading ... and Los Angeles, today announced the completion of the sale ... Troy Limited (Nasdaq: HELE). Kaz is an international leader in ... valued at $260 million subject to certain closing working capital ...
... The MED Group, a Managed Health Care Associates, Inc. ...  The website was created to help answer questions for ... about competitive bidding and how patients can receive their ... Centers for Medicare and Medicaid Services (CMS) will be ...
Cached Medicine Technology:Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 2Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 3New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 2New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 3
(Date:8/27/2014)... of hormone therapy has spawned a prevalent but preventable ... hot flashes, according to a study by a Yale ... the study published in the Aug. 27 online issue ... that moderate to severe hot flashes also called ... women. Women with VMS experience more than feeling hot; ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Michigan Head & Neck Institute is hosting a school ... school by ensuring they have everything they need for a ... Michigan Head & Neck Institute wants to ensure the children ... "There are a lot of military families in the area, ... back to our community," said Lauren Taylor, Marketing Coordinator at ...
(Date:8/27/2014)... Dr. Stewart Shofner and Dr. Kevin ... suffering from impaired vision. Some of the most common ... . Recently, Dr. Shofner has noticed a significant increase ... and also online. To help patients understand the facts, ... , 1)    Myth: People with perfect vision won’t develop glaucoma. ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... Third Quarter 2007 Results For the quarter ... of $734,347 or $0.06 loss per basic and diluted ... loss per basic and diluted share for the,same period ...
... Nov. 14 (HealthDay News) -- A protein that may have ... be a biomarker that indicates severe asthma. And it may ... to new research. , Reporting in the Nov. 15 issue ... University researchers said that people with severe asthma were more ...
... aim . . . , As the ... a high performance bullet based on technology developed at ... precision and superior terminal ballistics and is lead-free and ... Wakeman, Ohio, the technology is first being made available ...
... Reason for their added survival remains unclear, scientists say ... Hispanics appear to live longer following an Alzheimer,s diagnosis ... men and women of Asian and American Indian descent ... expectancies equivalent to that of white Alzheimer,s patients, ...
... December 31, RICHARDSON, Texas, Nov. 14 Blue ... will offer three Medicare Part D,prescription drug plans with ... Medicare beneficiaries in Texas can sign up,for or switch ... open enrollment period, which begins November 15 and continues ...
... Inc. announced today that CC Detect(SM), the ... now available from Panacea,Laboratories. CC Detect(SM) is ... identification of individuals with cancer of the ... standard screening methods. Panacea Laboratories,a division of ...
Cached Medicine News:Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 5Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Story tips from the Department of Energy's Oak Ridge National Laboratory, Nov. 2007 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Blue Cross and Blue Shield of Texas Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 3Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 4Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: